Study: The Poor Get Less Sleep, Leading to Greater Risk of Heart Disease
Research shows that a lack of sleep is a significant factor in the occurrence of heart disease among low-income people.
Research shows that a lack of sleep is a significant factor in the occurrence of heart disease among low-income people.
Aslan Pharmaceuticals shares jumped on Monday after the firm announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of its treatment of moderate-to-severe atopic dermatitis.
Aquestive Therapeutics shares jumped early on Monday after the firm announced the completion of its rolling submission of a New Drug Application (NDA) to the FDA for its therapeutic candidate Libervant.
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of December.
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of December.
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The November 15 short interest data has been compared with the previous report, and short interest in most of these…
A report that activist investor firm Starboard Value had taken a stake in CVS momentarily lifted the drugstore and health insurer's share price.
ChemoCentryx shares more than tripled on Tuesday after the firm, in conjunction with Vifor Fresenius Medical Care Renal Pharma, announced positive topline data from its late-stage trial of avacopan for the treatment of patients…
Global Blood Therapeutics shares jumped on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta (voxelotor) tablets for the treatment of sickle cell disease…
Medicines Co shares shot up on Monday after it was reported that Novartis will be acquiring the firm. The transaction was unanimously approved by the boards of directors of both companies.
Aquestive Therapeutics shares jumped on Monday after the firm announced that its treatment of amyotrophic lateral sclerosis (ALS), Exservan, received early-action approval from the U.S. Food and Drug Administration (FDA).
Iovance Bio announced results from a subgroup analysis of metastatic melanoma patients in its Phase 2 study of lifileucel.
ProQR Therapeutics shares jumped early on Thursday after the firm announced that it received an approval from the FDA for its autosomal dominant retinitis pigmentosa drug.
Aravive shares skyrocketed on Wednesday after the firm announced early-stage data for its ovarian cancer treatment.